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Abstract
Background: Cefoperazone has not been reported to cause vasculitic complications before.
Here, we report a case of hypersensitivity vasculitis associated with cefoperazone/sulbactam.
Case presentation: A 13-year-old girl with appendicitis developed hypersensitivity vasculitis on
the fifth day of cefoperazone/sulbactam therapy. Hypersensitivity vasculitis resolved gradually after
removal of the agent on the seventh day and did not recur. Although hypersensitivity vasculitis has
multiple causes, coexistence of hypersensitivity vasculitis and cefoperazone treatment, and the
quite resolution of the disease after removal of the drug, strongly favours a causative relationship.
Conclusion: To our knowledge, this is the first report of a hypersensitivity vasculitis associated
with cefoperazone.
Background
Cefoperazone is a common antibiotic drug used mainly to
treat serious infections. Reported adverse effects of this
drug include urticaria, maculopapular and erythematous
skin rash and rarely anaphylaxis and bronchospasm [1,2].
Cefoperazone has not been reported to cause vasculitic
complications before. We report a case of hypersensitivity
vasculitis associated with cefoperazone/sulbactam.
Case Presentation
A 13-year-old girl was admitted to Ondokuz May1s Uni-
versity Hospital with a 3-day history of abdominal pain
and fever. She had no history of allergic reactions, connec-
tive tissue disease, respiratory tract infection and/or use of
antibiotics or another drug. Physical examination re-
vealed abdominal tenderness and defense, and positive
Rovsing's sign in the right lower quadrant. The white-cell
count was 20.700 per cubic milimeter with 78 percent
neutrophils, 20 percent lymphocytes and 2 percent
monocytes. Hemoglobin was 12.1 g/dl. Erythrocyte sedi-
mentation rate (ESR) was slightly elevated at 46 mm/
hour. The patient was referred to the pediatric surgery de-
partment and acute perforated appendicitis was consid-
ered. Cefoperazone/sulbactam 100 mg/kg/day two in
divided doses was initiated on the first day of admission.
Abdominal exploration was performed on the second day
of admission and a gangrenous appendicitis with adhe-
sions to peripheral tissue and purulent material around
the caecum was observed. Biopsy specimen revealed
necrosis of mucosa, excessively lymphocyte, neutrophil,
plasma cell infiltration in the layers of appendix, and gan-
grenous appendicitis. No vasculitic changes were ob-
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On the fifth day of admission, an erythematous maculo-
papular rash without edema developed symmetrically
along the legs and feet. By the 7th day the rash gradually
spread to buttocks and changed to slightly elevated palpa-
ble purpuric lesions 3 to 8 mm in diameter, all at the same
stage and which did not blanch on pressure. On the 7th
day of admission, assuming the antimicrobial agent was
the causative agent, cefoperazone/sulbactam regimen was
changed to ampicillin (200 mg/kg/day in four divided
doses) plus netilmycin (5 mg/kg/day in three divided dos-
es) and an antihistaminic (clemastine, 2 × 1 mg/per day)
was initiated. The patient was afebril after the 6th day of
admission. The patient had no vomiting, melena, abdom-
inal pain, arthritis or arthralgia. Antinuclear antibody
(ANA), anti-deoxyribonucleic acid (anti-DNA) and rheu-
matoid factor were negative. Serum complements (C3,
C4), prothrombin time, partial thromboplastin time, uri-
nalysis, platelet and white blood cell counts were normal.
Kidney and liver function tests were within normal limits.
A skin biopsy of a new purpuric lesion from the anterior
of the leg was done on the second day of the rash and was
revealed a cutaneous vasculitis characterized by perivascu-
lar mononuclear cell infiltration. Direct immunfluores-
cence revealed IgA, IgG and fibrin deposits on the vessel
walls. The cutaneous lesions faded within a few days and
disappeared on seventh day after discontinuation of cef-
operazone/sulbactam therapy. Ampicillin and netilmycin
as well as antihistaminic agent were administered for ten
days. The patient was discharged on the 18th day of hos-
pitalization. On periodic controls, she is quite well and
purpura no recurred.
Hypersensitivity vasculitis presents usually as drug or in-
fection induced purpura and involves dominantly the
small vessels. The disease has been reported to be trig-
gered by many factors including bacterial infections,
drugs, immun complexes, blood stasis and systemic dis-
ease [3]. The criteria of the classification of hypersensitiv-
ity vasculitis are age at disease onset >16 years, medication
at disease onset, palpable purpura, maculopapular rash
and biopsy showing granulocytes in a perivascular or ex-
travascular location. The presence of any 3 or more criteria
has been shown to have a sensitivity of 71% and a specif-
icity of 84% [4]. Our patient meets three of five criteria
(medication at disease onset, palpable purpura and mac-
ulopapular rash) for hypersensitivity vasculitis.
In hypersensitivity vasculitis, the pathogenic mechanism
responsible for the blood vessel injury seems to be a type
III immun complex reaction or a type IV cell mediated re-
action. When the triggering antigen is drug, the term "hy-
persensitivity" seems apt [5]. The vascular damage is
believed to be triggered by the deposition of immun com-
plexes in vessel walls, with activation of complement cas-
cade. Polymorphonuclear leukocytes then migrate to the
area and release lysosomal enzymes that damage blood
vessels, leading to extravasation of erythrocytes, fibrin
deposition, and necrosis. Because leukocytoclastic inflam-
mation is such a prominent feature, these lesions are re-
ferred to as "leukocytoclastic vasculitis". Hypersensitivity
vasculitis can be divided into neutrophilic and lymhocytic
subtypes. The former is frequently associated with hy-
pocomplementemia, whereas the latter is not [6]. Our pa-
tient was of lymhocytic type and complement level was
normal. In the literature, it is reported that lymphocytic
infiltration might represent the resolving phase of an im-
mun complex-mediated neutrophilic vasculitis in lesions
more than 48 hours old [7]. On the other hand, there was
no relationship between appendicitis and vasculitis. Al-
though IF characteristically shows IgA deposits within ves-
sel walls in HSP while, in most other types of
leukocytoclastic vasculitis, IgG or IgM deposits are seen
[8]. In our patient, lymphocytic infiltration may be due to
delayed biopsy in resolving phase and IgA and IgG depos-
its do not exclude a leukocytoclastic vasculitis.
Drugs are implicated in up to 10–30% of cases of hyper-
sensitivity vasculitis. Penicillins and sulfonamids are most
frequently associated with such a reaction, but many other
agents have been implicated as well [3,9]. The other more
common agents are antihypertensives, antiarrythmics, al-
lopurinol, cimetidine, furosemid, hydantoins, penicillins,
phenylbutazone, hydralazine and sulfonamides [10].
Since its introduction in 1985, the third generation cepha-
losporin antibiotic cefoperazone has gained widespread
use, and much information has accumulated about its
possible adverse effects. Hypersensitivity reactions are the
most common side effects. Urticaria, maculopapular and
erythematous rash are more common reactions than oth-
er immediate reactions such as anaphylaxis and bronchos-
pasm [1,2,11,12]. Although some anecdotal cases of
vasculitis have been reported related with cephotaxim, ce-
furoxim and cefprozil, cefoperazone has not been report-
ed to cause vasculitic complications before [13–15].
Conclusion
In the case presented here, occurence of the typical skin le-
sions after five days of intake of cefoperazone, in addition
to resolution of lesions on discontinuation of cefopera-
zone are strong evidence in support of a role of cefopera-
zone in the development of vasculitis. To our knowledge,
this is the first reported case of hypersensitivity vasculitis
associated with cefoperazone. We believe that cefopera-
zone may be considered among the possible drugs caus-
ing hypersensitivity vasculitis.Page 2 of 3
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